Karolinska Development AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.03.18	Karolinska Development's portfolio company Forendo Pharma announces the appointment of David Colpman to its Board of Directors (GlobeNewswire)
29.12.17	Karolinska Development's Chairman of the Board resigns from his position (GlobeNewswire)
21.12.17	BioArctic, a company in Karolinska Development's portfolio, announces that the Phase 2b study of BAN2401 in early Alzheimer's Disease continues toward 18-month endpoint (GlobeNewswire)
20.12.17	Karolinska Development's portfolio company Modus Therapeutics announces publication of Phase I/II data demonstrating anti-adhesive properties of sevuparin (GlobeNewswire)
14.12.17	Karolinska Development's portfolio company Promimic receives FDA approval for HAnano Surface for use on dental implants (GlobeNewswire)
13.12.17	Karolinska Development divests its holding in Lipidor (GlobeNewswire)
28.11.17	Karolinska Development announces outcome of the Extraordinary General Meeting (GlobeNewswire)
20.11.17	Umecrine Cognition announces first patient included in clinical Phase 2a study in patients with sleep disorder (GlobeNewswire)
06.11.17	Karolinska Development realizes value increase in the portfolio company BioArctic through a partial exit and receives SEK 35 million (GlobeNewswire)
03.11.17	Notice of EGM in Karolinska Development AB (GlobeNewswire)
31.10.17	Change of Number of Shares and Votes in Karolinska Development (GlobeNewswire)
31.10.17	Karolinska Development publishes Interim Report (January - September 2017) and reports a positive result for the third quarter (GlobeNewswire)
31.10.17	Changes in the Board of Directors at Karolinska Development (GlobeNewswire)
30.10.17	Karolinska Development divests its holdings in Xspray and receives SEK 12.5 million directly and additionally SEK 0.8 million via KCIF's sale (GlobeNewswire)
27.10.17	Karolinska Development divests its holdings in Xspray and receives SEK 12.5 million directly and additionally SEK 0.8 million via KCIF's sale (GlobeNewswire)
27.10.17	Karolinska Development - Interim Report (January-September 2017) - Invitation to conference call and webcast (GlobeNewswire)
16.10.17	The value of Karolinska Development's holdings in Umecrine Cognition increases with SEK 196 million owing to positive phase 1b data (GlobeNewswire)
16.10.17	Karolinska Development's portfolio company Aprea announces first patient enrolled in clinical phase 1b/2 study with APR-246 for the treatment of esophageal cancer (GlobeNewswire)
12.10.17	First day of trading in Karolinska Development's portfolio company BioArctic's shares on Nasdaq Stockholm (GlobeNewswire)
04.10.17	Karolinska Development's portfolio company Umecrine Cognition secures financing for clinical development of the drug candidate GR3027 against sleep disorders (GlobeNewswire)
28.09.17	Karolinska Development's former portfolio company Xspray Pharma is listed on Nasdaq First North (GlobeNewswire)
14.09.17	Karolinska Developments's portfolio company Modus Therapeutics recruits new Chief Medical Officer (GlobeNewswire)
13.09.17	Karolinska Development's portfolio company BioArctic intends to list on Nasdaq Stockholm (GlobeNewswire)
13.09.17	Karolinska Development's portfolio company Umecrine Cognition presents positive phase 1b data for its drug candidate against hepatic encephalopathy (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Karolinska Development AB (B)

Aktien Top/Flop

Meistgelesene Nachrichten